CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Creative Medical Technology Holdings, Inc.

CELZ

US22529Y4089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.32 ^USD	-1.82%		-10.19%	-6.29%

Mar. 22	Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	CI
Mar. 22	Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Creative Medical Technology Holdings, Inc. authorizes a Buyback Plan.

June 11, 2023

The Board of Directors of Creative Medical Technology Holdings, Inc. has authorized a buyback plan on June 12, 2023.

Latest news about Creative Medical Technology Holdings, Inc.

Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	Mar. 22	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201	Mar. 07	DJ
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access	Mar. 07	CI
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise	Mar. 06	MT
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures	Mar. 06	MT
Creative Medical Shares Rally Premarket on FDA Orphan Designation	Mar. 06	DJ
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony	Mar. 06	MT
Top Premarket Gainers	Mar. 06	MT
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem	Dec. 20	CI
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	Nov. 14	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain	23-10-10	CI
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem? (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain	23-09-19	CI
Top Premarket Gainers	23-09-13	MT
Top Premarket Gainers	23-08-21	MT
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	23-08-11	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Top Premarket Decliners	23-06-16	MT
Creative Medical Technology Holdings, Inc. announces an Equity Buyback for $2 million worth of its shares.	23-06-12	CI
Creative Medical Technology Holdings, Inc. authorizes a Buyback Plan.	23-06-11	CI
Creative Medical to Trade on 1-for-10 Reverse Stock-Split Basis Starting Monday	23-06-09	MT
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform	23-05-31	CI
Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development	23-05-22	CI
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line	23-05-18	CI

Chart Creative Medical Technology Holdings, Inc.

Duration

Period

Chart Creative Medical Technology Holdings, Inc.

More charts

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.32 USD

Average target price

30 USD

Spread / Average Target

+594.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.	-6.29%	5.86M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs